Follow-up analyses of clinicopathological characteristics revealed that patients with a better best overall response (BOR), higher PD-L1 expression level, either on the surface of tumor cells (TC) or immune cells (IC), and inflamed phenotypes, were allocated more in TME cluster A (Figure 3C, Table S1), which was identified to have a lower immune exclusion, and therefore, a potentially better anti-tumor immune response. Here, CD274 is linked to neoplasm.